+ Watch QLTI
on My Watchlist
A biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies.
QLT's ascent seems to have stuttered at about the 4.75 level although it remains close to its year high. Their only marketed product, Visudyne, is a niche ophthalmologic medication with declining revenues. They will continue to receive revenue from the Eligard sale but this is already baked into the market cap. I detect undercurrents of efficacy issues with the Punctum plug program. The only other short-term catalysts will be data from the DENALI and RADICAL studies of Visudyne, which I don't expect to reverse the decline of that product. The cash position is admittedly strong, but nothing has justified the recent rise in price for this historically weak stock.
There was recent insider buying, not that I disagree with you.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions